Despite lack of monospecific anti-DRw13 sera, a corresponding class II determinant can be defined by a DRw13 restricted anti-influenza virus T cell clone

Jean Michon(Université Paris Sciences et Lettres), J P Lévy(Hôpital Cochin), Yvette Hénin(Centre National de la Recherche Scientifique), Ghislaine Sterkers(Délégation Paris 7), L. Gebuhrer(Inserm), Alain Haziot(Inserm), Hervé Betuel(Inserm), Virginia Lepage(Inserm), E Gomard(Inserm), Anne Catherine Freidel(Inserm), Dominique Charron(Inserm)

Human Immunology

March 1, 1986

10.1016/0198-8859(86)90003-0

Cited by 8

Related Papers

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

|Nature Genetics|2015|563

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

|Blood|2006|431

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents

|Blood|2006|362

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

|The Lancet Oncology|2009|196

BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia

|The Journal of Immunology|2006|142